Worldwide Study Finder

Phase 2CompletedINTERVENTIONAL

Neo-adjuvant Abiraterone + Luteinizing Hormone-Releasing Hormone (LHRH) Versus LHRH in Prostate Cancer

ClinicalTrials.gov · NCT01088529 · Registry updated: 2014-05-15

Condition / research focus: Prostate Cancer
Sponsor: Cougar Biotechnology, Inc.
Countries with listed sites: United States
Registry dates and results: Start: 2009-12. Completion: 2013-03 (may be estimated). Results are posted in this registry.

Products and interventions (3)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Abiraterone Acetate (drug) — also listed as: CB7630
Prednisone (drug)
LHRHa (drug) — also listed as: Lupron®, leuprolide, Zoladex®, goserelin

Where the study takes place — 1 listed sites

Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.

Facility not reportedHouston, Texas, United States

Phase 1CompletedINTERVENTIONAL

Influence of Male Hormones on Regional Fat Metabolism

ClinicalTrials.gov · NCT01160328 · Registry updated: 2014-05-14

Condition / research focus: Obesity
Sponsor: Mayo Clinic
Countries with listed sites: United States
Registry dates and results: Start: 2010-06. Completion: 2013-01 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Leuprolide (drug) — also listed as: Lupron
Testosterone (drug) — also listed as: AndroGel

Where the study takes place — 1 listed sites

Mayo Clinic
Rochester, Minnesota, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 2CompletedINTERVENTIONAL

A Long-term Extension Study of TAK-385 in the Treatment of Endometriosis

ClinicalTrials.gov · NCT01452685 · Registry updated: 2014-05-08

Condition / research focus: Endometriosis
Sponsor: Takeda
Countries with listed sites: Japan
Registry dates and results: Start: 2012-03. Completion: 2013-12 (may be estimated). No results posted in this registry response.

Products and interventions (5)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Placebo (drug)
TAK-385 (drug)
TAK-385 (drug)
TAK-385 (drug)
Leuprorelin acetate (drug) — also listed as: Leuplin

Where the study takes place — 69 listed sites

Facility not reported
Nagoya, Aichi-ken, Japan
Site recruitment: Not reported
Facility not reported
Chiba, Chiba, Japan
Site recruitment: Not reported
Facility not reported
Funabashi-shi, Chiba, Japan
Site recruitment: Not reported
Facility not reported
Ichihara-shi, Chiba, Japan
Site recruitment: Not reported
Facility not reported
Yachiyo-shi, Chiba, Japan
Site recruitment: Not reported
Facility not reported
Nihama-shi, Ehime, Japan
Site recruitment: Not reported
Facility not reported
Fukui-shi, Fukui, Japan
Site recruitment: Not reported
Facility not reported
Fukuoka, Fukuoka, Japan
Site recruitment: Not reported
Facility not reported
Iizuka-shi, Fukuoka, Japan
Site recruitment: Not reported
Facility not reported
Kitakyushu-shi, Fukuoka, Japan
Site recruitment: Not reported
Facility not reported
Onga-gun, Fukuoka, Japan
Site recruitment: Not reported
Facility not reported
Yanagawa-shi, Fukuoka, Japan
Site recruitment: Not reported
Facility not reported
Koriyama-shi, Fukushima, Japan
Site recruitment: Not reported
Facility not reported
Takayama-shi, Gifu, Japan
Site recruitment: Not reported
Facility not reported
Takasaki-shi, Gunma, Japan
Site recruitment: Not reported
Facility not reported
Hirosima-shi, Hiroshima, Japan
Site recruitment: Not reported
Facility not reported
Ebetsu-shi, Hokkaido, Japan
Site recruitment: Not reported
Facility not reported
Ishikari-shi, Hokkaido, Japan
Site recruitment: Not reported
Facility not reported
Sapporo, Hokkaido, Japan
Site recruitment: Not reported
Facility not reported
Amagasaki-shi, Hyōgo, Japan
Site recruitment: Not reported
Facility not reported
Kako-gun, Hyōgo, Japan
Site recruitment: Not reported
Facility not reported
Kawanishi-shi, Hyōgo, Japan
Site recruitment: Not reported
Facility not reported
Kobe, Hyōgo, Japan
Site recruitment: Not reported
Facility not reported
Kanazawa, Ishikawa-ken, Japan
Site recruitment: Not reported
Facility not reported
Marugame-shi, Kagawa-ken, Japan
Site recruitment: Not reported
Facility not reported
Kagoshima, Kagoshima-ken, Japan
Site recruitment: Not reported
Facility not reported
Hiratsuka-shi, Kanagawa, Japan
Site recruitment: Not reported
Facility not reported
Kamakura-shi, Kanagawa, Japan
Site recruitment: Not reported
Facility not reported
Kawasaki-shi, Kanagawa, Japan
Site recruitment: Not reported
Facility not reported
Yamato-shi, Kanagawa, Japan
Site recruitment: Not reported
Facility not reported
Yokohama, Kanagawa, Japan
Site recruitment: Not reported
Facility not reported
Nankoku-shi, Kochi, Japan
Site recruitment: Not reported
Facility not reported
Kumamoto, Kumamoto, Japan
Site recruitment: Not reported
Facility not reported
Kyoto, Kyoto, Japan
Site recruitment: Not reported
Facility not reported
Sendai, Miyagi, Japan
Site recruitment: Not reported
Facility not reported
Matsumoto-shi, Nagano, Japan
Site recruitment: Not reported
Facility not reported
Nagano, Nagano, Japan
Site recruitment: Not reported
Facility not reported
Suzaka-shi, Nagano, Japan
Site recruitment: Not reported
Facility not reported
Nara, Nara, Japan
Site recruitment: Not reported
Facility not reported
Ōita, Oita Prefecture, Japan
Site recruitment: Not reported
Facility not reported
Kurashiki-shi, Okayama-ken, Japan
Site recruitment: Not reported
Facility not reported
Okayama, Okayama-ken, Japan
Site recruitment: Not reported
Facility not reported
Hirakata-shi, Osaka, Japan
Site recruitment: Not reported
Facility not reported
Ibaraki-shi, Osaka, Japan
Site recruitment: Not reported
Facility not reported
Ikeda-shi, Osaka, Japan
Site recruitment: Not reported
Facility not reported
Osaka, Osaka, Japan
Site recruitment: Not reported
Facility not reported
Sakai-shi, Osaka, Japan
Site recruitment: Not reported
Facility not reported
Suita-shi, Osaka, Japan
Site recruitment: Not reported
Facility not reported
Tondabayashi-shi, Osaka, Japan
Site recruitment: Not reported
Facility not reported
Toyonaka-shi, Osaka, Japan
Site recruitment: Not reported
Facility not reported
Iruma-shi, Saitama, Japan
Site recruitment: Not reported
Facility not reported
Kusatsu-shi, Shiga, Japan
Site recruitment: Not reported
Facility not reported
Hamamatsu, Shizuoka, Japan
Site recruitment: Not reported
Facility not reported
Numazu-shi, Shizuoka, Japan
Site recruitment: Not reported
Facility not reported
Yaizu-shi, Shizuoka, Japan
Site recruitment: Not reported
Facility not reported
Komatsushima-shi, Tokushima, Japan
Site recruitment: Not reported
Facility not reported
Naruto-shi, Tokushima, Japan
Site recruitment: Not reported
Facility not reported
Bunkyo-ku, Tokyo, Japan
Site recruitment: Not reported
Facility not reported
Chiyoda-ku, Tokyo, Japan
Site recruitment: Not reported
Facility not reported
Chuo-ku, Tokyo, Japan
Site recruitment: Not reported
Facility not reported
Machida-shi, Tokyo, Japan
Site recruitment: Not reported
Facility not reported
Minato-ku, Tokyo, Japan
Site recruitment: Not reported
Facility not reported
Ohta-ku, Tokyo, Japan
Site recruitment: Not reported
Facility not reported
Setagaya-ku, Tokyo, Japan
Site recruitment: Not reported
Facility not reported
Shinagawa-ku, Tokyo, Japan
Site recruitment: Not reported
Facility not reported
Suginami-ku, Tokyo, Japan
Site recruitment: Not reported
Facility not reported
tabashi City, Tokyo, Japan
Site recruitment: Not reported
Facility not reported
Toyama, Toyama, Japan
Site recruitment: Not reported
Facility not reported
Yamaguchi, Yamaguchi, Japan
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Not applicableUnknownINTERVENTIONAL

The Effect of GnRH Agonist Administered in the Luteal Phase on ART Cycle Outcomes

ClinicalTrials.gov · NCT02114645 · Registry updated: 2014-04-15

Condition / research focus: Infertility
Sponsor: Zekai Tahir Burak Women's Health Research and Education Hospital
Countries with listed sites: Turkey (Türkiye)
Registry dates and results: Start: 2014-04. Completion: 2015-04 (may be estimated). No results posted in this registry response.

Products and interventions (3)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Leuprolide acetate (drug) — also listed as: lucrin
vaginal progesterone (drug) — also listed as: crinone gel
4 mg oral estradiol valerate (drug) — also listed as: estrofem 2mg tablet

Where the study takes place — 1 listed sites

Zekai Tahir Burak Hospital
Ankara, Cankaya, Turkey (Türkiye)
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 1WithdrawnINTERVENTIONAL

The JET Study: a Phase I Trial of Cabazitaxel, Radiotherapy and Long-term Androgen Deprivation

ClinicalTrials.gov · NCT01981668 · Registry updated: 2014-03-19

Condition / research focus: Prostatic Neoplasms
Sponsor: Nova Scotia Cancer Centre
Countries with listed sites: No country reported
Registry dates and results: Start: Not reported. Completion: Not reported (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

cabazitaxel (drug) — also listed as: Jevtana

Where the study takes place — 0 listed sites

The registry does not list facilities in this record. This does not mean the study has no sites.

Original record, eligibility, contacts and results →

Phase 2UnknownINTERVENTIONAL

The ELDORADO (Eligard®, Docetaxel and Radiotherapy) Study

ClinicalTrials.gov · NCT00452556 · Registry updated: 2014-03-19

Condition / research focus: Prostatic Neoplasms
Sponsor: Nova Scotia Cancer Centre
Countries with listed sites: Canada
Registry dates and results: Start: 2007-05. Completion: 2017-02 (may be estimated). No results posted in this registry response.

Products and interventions (4)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Docetaxel (drug) — also listed as: Taxotere
Leuprolide Acetate (Eligard®) (drug) — also listed as: Androgen deprivation
Intensity-Modulated Radiotherapy (radiation) — also listed as: Radiotherapy
Intensity-Modulated Radiotherapy (radiation) — also listed as: Radiotherapy

Where the study takes place — 1 listed sites

Nova Scotia Cancer Centre
Halifax, Nova Scotia, Canada
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 3UnknownINTERVENTIONAL

Androgen Suppression Combined With Elective Nodal and Dose Escalated Radiation Therapy

ClinicalTrials.gov · NCT00175396 · Registry updated: 2014-03-17

Condition / research focus: Prostate Cancer
Sponsor: University of British Columbia
Countries with listed sites: Canada
Registry dates and results: Start: 2004-05. Completion: 2014-06 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Androgen suppression, radiotherapy (procedure) — also listed as: Androgen suppression: non-steroidal androgen (any of flutamide, nilutamide or bicalutamide (bicalutamide is almost always used)., LHRH monotherapy: buserelin acetate or leuprolide acetate.
Androgen suppression, radiotherapy, iodine 125 brachytherapy (procedure)

Where the study takes place — 1 listed sites

BC Cancer Agency
Vancouver, British Columbia, Canada
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 2CompletedINTERVENTIONAL

Efficacy and Safety of TAK-385 in the Treatment of Endometriosis

ClinicalTrials.gov · NCT01458301 · Registry updated: 2014-02-25

Condition / research focus: Endometriosis
Sponsor: Takeda
Countries with listed sites: Japan
Registry dates and results: Start: 2011-10. Completion: 2013-08 (may be estimated). No results posted in this registry response.

Products and interventions (5)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Placebo (drug)
TAK-385 (drug)
TAK-385 (drug)
TAK-385 (drug)
Leuprorelin acetate (drug) — also listed as: Leuplin

Where the study takes place — 69 listed sites

Facility not reported
Nagoya, Aichi-ken, Japan
Site recruitment: Not reported
Facility not reported
Chiba, Chiba, Japan
Site recruitment: Not reported
Facility not reported
Funabashi-shi, Chiba, Japan
Site recruitment: Not reported
Facility not reported
Ichihara-shi, Chiba, Japan
Site recruitment: Not reported
Facility not reported
Yachiyo-shi, Chiba, Japan
Site recruitment: Not reported
Facility not reported
Nihama-shi, Ehime, Japan
Site recruitment: Not reported
Facility not reported
Fukui-shi, Fukui, Japan
Site recruitment: Not reported
Facility not reported
Fukuoka, Fukuoka, Japan
Site recruitment: Not reported
Facility not reported
Iizuka-shi, Fukuoka, Japan
Site recruitment: Not reported
Facility not reported
Kitakyushu-shi, Fukuoka, Japan
Site recruitment: Not reported
Facility not reported
Onga-gun, Fukuoka, Japan
Site recruitment: Not reported
Facility not reported
Yanagawa-shi, Fukuoka, Japan
Site recruitment: Not reported
Facility not reported
Koriyama-shi, Fukushima, Japan
Site recruitment: Not reported
Facility not reported
Takayama-shi, Gifu, Japan
Site recruitment: Not reported
Facility not reported
Takasaki-shi, Gunma, Japan
Site recruitment: Not reported
Facility not reported
Hirosima-shi, Hiroshima, Japan
Site recruitment: Not reported
Facility not reported
Ebetsu-shi, Hokkaido, Japan
Site recruitment: Not reported
Facility not reported
Ishikari-shi, Hokkaido, Japan
Site recruitment: Not reported
Facility not reported
Sapporo, Hokkaido, Japan
Site recruitment: Not reported
Facility not reported
Amagasaki-shi, Hyōgo, Japan
Site recruitment: Not reported
Facility not reported
Kako-gun, Hyōgo, Japan
Site recruitment: Not reported
Facility not reported
Kawanishi-shi, Hyōgo, Japan
Site recruitment: Not reported
Facility not reported
Kobe, Hyōgo, Japan
Site recruitment: Not reported
Facility not reported
Kanazawa, Ishikawa-ken, Japan
Site recruitment: Not reported
Facility not reported
Marugame-shi, Kagawa-ken, Japan
Site recruitment: Not reported
Facility not reported
Kagoshima, Kagoshima-ken, Japan
Site recruitment: Not reported
Facility not reported
Hiratsuka-shi, Kanagawa, Japan
Site recruitment: Not reported
Facility not reported
Kamakura-shi, Kanagawa, Japan
Site recruitment: Not reported
Facility not reported
Kawasaki-shi, Kanagawa, Japan
Site recruitment: Not reported
Facility not reported
Yamato-shi, Kanagawa, Japan
Site recruitment: Not reported
Facility not reported
Yokohama, Kanagawa, Japan
Site recruitment: Not reported
Facility not reported
Nankoku-shi, Kochi, Japan
Site recruitment: Not reported
Facility not reported
Kumamoto, Kumamoto, Japan
Site recruitment: Not reported
Facility not reported
Kyoto, Kyoto, Japan
Site recruitment: Not reported
Facility not reported
Sendai, Miyagi, Japan
Site recruitment: Not reported
Facility not reported
Matsumoto-shi, Nagano, Japan
Site recruitment: Not reported
Facility not reported
Nagano, Nagano, Japan
Site recruitment: Not reported
Facility not reported
Suzaka-shi, Nagano, Japan
Site recruitment: Not reported
Facility not reported
Nara, Nara, Japan
Site recruitment: Not reported
Facility not reported
Ōita, Oita Prefecture, Japan
Site recruitment: Not reported
Facility not reported
Kurashiki-shi, Okayama-ken, Japan
Site recruitment: Not reported
Facility not reported
Okayama, Okayama-ken, Japan
Site recruitment: Not reported
Facility not reported
Hirakata-shi, Osaka, Japan
Site recruitment: Not reported
Facility not reported
Ibaraki-shi, Osaka, Japan
Site recruitment: Not reported
Facility not reported
Ikeda-shi, Osaka, Japan
Site recruitment: Not reported
Facility not reported
Osaka, Osaka, Japan
Site recruitment: Not reported
Facility not reported
Sakai-shi, Osaka, Japan
Site recruitment: Not reported
Facility not reported
Suita-shi, Osaka, Japan
Site recruitment: Not reported
Facility not reported
Tondabayashi-shi, Osaka, Japan
Site recruitment: Not reported
Facility not reported
Toyonaka-shi, Osaka, Japan
Site recruitment: Not reported
Facility not reported
Iruma-shi, Saitama, Japan
Site recruitment: Not reported
Facility not reported
Kusatsu-shi, Shiga, Japan
Site recruitment: Not reported
Facility not reported
Hamamatsu, Shizuoka, Japan
Site recruitment: Not reported
Facility not reported
Numazu-shi, Shizuoka, Japan
Site recruitment: Not reported
Facility not reported
Yaizu-shi, Shizuoka, Japan
Site recruitment: Not reported
Facility not reported
Komatsushima-shi, Tokushima, Japan
Site recruitment: Not reported
Facility not reported
Naruto-shi, Tokushima, Japan
Site recruitment: Not reported
Facility not reported
Bunkyo-ku, Tokyo, Japan
Site recruitment: Not reported
Facility not reported
Chiyoda-ku, Tokyo, Japan
Site recruitment: Not reported
Facility not reported
Chuo-ku, Tokyo, Japan
Site recruitment: Not reported
Facility not reported
Machida-shi, Tokyo, Japan
Site recruitment: Not reported
Facility not reported
Minato-ku, Tokyo, Japan
Site recruitment: Not reported
Facility not reported
Ohta-ku, Tokyo, Japan
Site recruitment: Not reported
Facility not reported
Setagaya-ku, Tokyo, Japan
Site recruitment: Not reported
Facility not reported
Shinagawa-ku, Tokyo, Japan
Site recruitment: Not reported
Facility not reported
Suginami-ku, Tokyo, Japan
Site recruitment: Not reported
Facility not reported
tabashi City, Tokyo, Japan
Site recruitment: Not reported
Facility not reported
Toyama, Toyama, Japan
Site recruitment: Not reported
Facility not reported
Yamaguchi, Yamaguchi, Japan
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 3CompletedINTERVENTIONAL

Medical Treatment of Endometriosis-Associated Pelvic Pain

ClinicalTrials.gov · NCT00229996 · Registry updated: 2014-01-24

Condition / research focus: Endometriosis; Pelvic Pain
Sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Countries with listed sites: United States
Registry dates and results: Start: 2004-07. Completion: Not reported (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Oral Contraceptive (drug)
Depot-Leuprolide/Norethindrone (drug)

Where the study takes place — 1 listed sites

Brigham and Womens Hospital
Boston, Massachusetts, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 4UnknownINTERVENTIONAL

The Comparison of Effect of Four Different Treatment Protocols on IVF Outcomes in Poor Responders Undergoing in Vitro Fertilization.

ClinicalTrials.gov · NCT01948804 · Registry updated: 2014-01-15

Condition / research focus: Poor Responders Undergoing IVF
Sponsor: Pınar Özcan Cenksoy
Countries with listed sites: No country reported
Registry dates and results: Start: 2014-01. Completion: Not reported (may be estimated). No results posted in this registry response.

Products and interventions (4)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

GnrH Antagonist/letrozole protocol (Cetrotide; serono + Femara; Novartis Pharma AG) (drug)
microdose flare-up protocol (Lucrin; Abbott + Gonal F, Serono) (drug)
Antagonist/clomiphene protocol (Cetrotide; serono + Klomen, Kocak pharma) (drug)
GnRH antagonist protocol (Cetrotide, Serono) (drug)

Where the study takes place — 0 listed sites

The registry does not list facilities in this record. This does not mean the study has no sites.

Original record, eligibility, contacts and results →

Phase not reported / not applicableCompletedOBSERVATIONAL

Observational, Non-interventional, Non Comparative Real Life Data Collection of Depo-Eligard® 7.5 mg, 22.5 mg and 45 mg in Male Prostate Cancer Patients

ClinicalTrials.gov · NCT01793077 · Registry updated: 2014-01-13

Condition / research focus: Prostate Cancer
Sponsor: Astellas Pharma Europe B.V.
Countries with listed sites: Belgium
Registry dates and results: Start: 2011-12. Completion: 2013-12 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Depo-Eligard® (drug) — also listed as: Leuprolide Acetate

Where the study takes place — 23 listed sites

Site: 5
Antwerp, Antwerp, Belgium
Site recruitment: Not reported
Site: 8
Antwerp, Antwerp, Belgium
Site recruitment: Not reported
Site: 9
Antwerp, Antwerp, Belgium
Site recruitment: Not reported
Site: 14
Antwerp, Antwerp, Belgium
Site recruitment: Not reported
Site: 4
Antwerp, Antwerp, Belgium
Site recruitment: Not reported
Site: 33
Merksem, Antwerp, Belgium
Site recruitment: Not reported
Site: 1
Turnhout, Antwerp, Belgium
Site recruitment: Not reported
Site: 23
Brussels, Brussels Capital, Belgium
Site recruitment: Not reported
Site: 13
Brussels, Brussels Capital, Belgium
Site recruitment: Not reported
Site: 24
Uccle, Brussels Capital, Belgium
Site recruitment: Not reported
Site: 32
Aalst, East Flanders, Belgium
Site recruitment: Not reported
Site: 34
Dendermonde, East Flanders, Belgium
Site recruitment: Not reported
Site: 11
Ghent, East Flanders, Belgium
Site recruitment: Not reported
Site: 17
Oudenaarde, East Flanders, Belgium
Site recruitment: Not reported
Site: 18
Tienen, Flemish Brabant, Belgium
Site recruitment: Not reported
Site: 39
La Louvière, Hainaut, Belgium
Site recruitment: Not reported
Site: 37
Sint-Truiden, Limburg, Belgium
Site recruitment: Not reported
Site: 38
Liège, Liège, Belgium
Site recruitment: Not reported
Site: 26
Lasne-Chapelle-Saint-Lambert, Walloon Brabant, Belgium
Site recruitment: Not reported
Site: 21
Ieper, West Flanders, Belgium
Site recruitment: Not reported
Site: 20
Izegem, West Flanders, Belgium
Site recruitment: Not reported
Site: 25
Kortijk, West Flanders, Belgium
Site recruitment: Not reported
Site: 31
Ostend, West Flanders, Belgium
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 3CompletedINTERVENTIONAL

Safety Extension Study Of Leuprolide Acetate (Lupron Depot) In The Treatment Of Central Precocious Puberty

ClinicalTrials.gov · NCT00667446 · Registry updated: 2014-01-09

Condition / research focus: Precocious; Leuprolide Acetate; Luteinizing Hormone (LH); Gonadotrophin-releasing Hormone Agonist (GnRHa); Tanner Staging; Depot Formulation; Suppression of LH; Central Precocious Puberty (CPP); Gonadotrophin-releasing Hormone (GnRH); Lupron; GnRH Analog; Pediatrics Central Precocious Puberty
Sponsor: AbbVie (prior sponsor, Abbott)
Countries with listed sites: Puerto Rico · United States
Registry dates and results: Start: 2008-12. Completion: 2013-01 (may be estimated). Results are posted in this registry.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Leuprolide Acetate 3 Month Depot (drug) — also listed as: ABT-818, Lupron, Leuprorelin acetate

Where the study takes place — 20 listed sites

Site Reference ID/Investigator# 13521
Birmingham, Alabama, United States
Site recruitment: Not reported
Site Reference ID/Investigator# 14922
Long Beach, California, United States
Site recruitment: Not reported
Site Reference ID/Investigator# 26043
Los Angeles, California, United States
Site recruitment: Not reported
Site Reference ID/Investigator# 20802
San Diego, California, United States
Site recruitment: Not reported
Site Reference ID/Investigator# 22425
Greenwood Village, Colorado, United States
Site recruitment: Not reported
Site Reference ID/Investigator# 18181
Jacksonville, Florida, United States
Site recruitment: Not reported
Site Reference ID/Investigator# 26364
Pensacola, Florida, United States
Site recruitment: Not reported
Site Reference ID/Investigator# 26983
Indianapolis, Indiana, United States
Site recruitment: Not reported
Site Reference ID/Investigator# 20821
Shreveport, Louisiana, United States
Site recruitment: Not reported
Site Reference ID/Investigator# 23643
Minneapolis, Minnesota, United States
Site recruitment: Not reported
Site Reference ID/Investigator# 23502
Saint Paul, Minnesota, United States
Site recruitment: Not reported
Site Reference ID/Investigator# 14121
Kansas City, Missouri, United States
Site recruitment: Not reported
Site Reference ID/Investigator# 23802
Oklahoma City, Oklahoma, United States
Site recruitment: Not reported
Site Reference ID/Investigator# 13324
Tulsa, Oklahoma, United States
Site recruitment: Not reported
Site Reference ID/Investigator# 16506
Hershey, Pennsylvania, United States
Site recruitment: Not reported
Site Reference ID/Investigator# 14024
Seattle, Washington, United States
Site recruitment: Not reported
Site Reference ID/Investigator# 23182
Bayamón, Puerto Rico
Site recruitment: Not reported
Site Reference ID/Investigator# 21721
Ponce, Puerto Rico
Site recruitment: Not reported
Site Reference ID/Investigator# 25908
Rio Piedras, Puerto Rico
Site recruitment: Not reported
Site Reference ID/Investigator# 23082
San Juan, Puerto Rico
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 2CompletedINTERVENTIONAL

Hormone Therapy Plus Radiation Therapy in Treating Patients With Prostate Cancer

ClinicalTrials.gov · NCT00003124 · Registry updated: 2014-01-06

Condition / research focus: Prostate Cancer
Sponsor: Herbert Irving Comprehensive Cancer Center
Countries with listed sites: United States
Registry dates and results: Start: 1997-05. Completion: 2007-01 (may be estimated). No results posted in this registry response.

Products and interventions (3)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

flutamide (drug)
leuprolide acetate (drug)
radiation therapy (radiation)

Where the study takes place — 1 listed sites

Herbert Irving Comprehensive Cancer Center
New York, New York, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 3CompletedINTERVENTIONAL

Tamoxifen, Ovarian Ablation, and/or Combination Chemotherapy in Treating Premenopausal Women With Stage I, Stage II, or Stage IIIA Invasive Breast Cancer

ClinicalTrials.gov · NCT00002580 · Registry updated: 2013-11-06

Condition / research focus: Breast Cancer
Sponsor: Scottish Cancer Therapy Network
Countries with listed sites: United Kingdom
Registry dates and results: Start: 1993-06. Completion: Not reported (may be estimated). No results posted in this registry response.

Products and interventions (10)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

cyclophosphamide (drug)
fluorouracil (drug)
goserelin acetate (drug)
leuprolide acetate (drug)
methotrexate (drug)
tamoxifen citrate (drug)
conventional surgery (procedure)
laparoscopic surgery (procedure)
oophorectomy (procedure)
radiation therapy (radiation)

Where the study takes place — 10 listed sites

University Hospitals of Leicester
Leicester, England, United Kingdom
Site recruitment: Not reported
Aberdeen Royal Infirmary
Aberdeen, Scotland, United Kingdom
Site recruitment: Not reported
Ninewells Hospital and Medical School
Dundee, Scotland, United Kingdom
Site recruitment: Not reported
Western General Hospital
Edinburgh, Scotland, United Kingdom
Site recruitment: Not reported
Beatson Oncology Centre
Glasgow, Scotland, United Kingdom
Site recruitment: Not reported
University of Glasgow
Glasgow, Scotland, United Kingdom
Site recruitment: Not reported
Raigmore Hospital
Inverness, Scotland, United Kingdom
Site recruitment: Not reported
Royal Alexandra Hospital
Paisley, Scotland, United Kingdom
Site recruitment: Not reported
Ayr Hospital
Ayr, United Kingdom
Site recruitment: Not reported
Falkirk Royal Infirmary
Falkirk, United Kingdom
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 3TerminatedINTERVENTIONAL

A Study of Androgen Deprivation With Leuprolide, +/- Docetaxel for Clinically Asymptomatic Prostate Cancer Participants With a Rising Prostate Specific Antigen (PSA)

ClinicalTrials.gov · NCT00514917 · Registry updated: 2013-11-04

Condition / research focus: Prostatic Neoplasms
Sponsor: Sanofi
Countries with listed sites: Belgium · Canada · Czechia · Germany · Lithuania · Poland · Slovakia · Spain · United States
Registry dates and results: Start: 2007-07. Completion: 2012-09 (may be estimated). Results are posted in this registry.

Products and interventions (3)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Docetaxel (drug) — also listed as: TAXOTERE®, XRP6976
Leuprolide (drug) — also listed as: Eligard®
Bicalutamide (drug)

Where the study takes place — 9 listed sites

Sanofi-Aventis Administrative Office
Bridgewater, New Jersey, United States
Site recruitment: Not reported
Sanofi-Aventis Administrative Office
Diegem, Belgium
Site recruitment: Not reported
Sanofi-Aventis Administrative Office
Laval, Canada
Site recruitment: Not reported
Sanofi-Aventis Administrative Office
Prague, Czechia
Site recruitment: Not reported
Sanofi-Aventis Administrative Office
Frankfurt, Germany
Site recruitment: Not reported
Sanofi-Aventis Administrative Office
Vilnius, Lithuania
Site recruitment: Not reported
Sanofi-Aventis Administrative Office
Warsaw, Poland
Site recruitment: Not reported
Sanofi-Aventis Administrative Office
Bratislava, Slovakia
Site recruitment: Not reported
Sanofi-Aventis Administrative Office
Barcelona, Spain
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 4CompletedINTERVENTIONAL

Randomized Crossover Trial to Assess the Tolerability of Gonadotropin Releasing Hormone (GnRH) Analogue Administration

ClinicalTrials.gov · NCT01161563 · Registry updated: 2013-09-06

Condition / research focus: Prostate Cancer
Sponsor: Watson Pharmaceuticals
Countries with listed sites: United States
Registry dates and results: Start: 2010-07. Completion: 2011-04 (may be estimated). Results are posted in this registry.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Triptorelin pamoate (drug)
Leuprolide acetate (drug)

Where the study takes place — 16 listed sites

Watson Investigational Site
Homewood, Alabama, United States
Site recruitment: Not reported
Watson Investigational Site
Daytona Beach, Florida, United States
Site recruitment: Not reported
Watson Investigational Site
Orange City, Florida, United States
Site recruitment: Not reported
Watson Investigational Site
Coeur d'Alene, Idaho, United States
Site recruitment: Not reported
Watson Investigational Site
Carmel, Indiana, United States
Site recruitment: Not reported
Watson Investigational Site
Jeffersonville, Indiana, United States
Site recruitment: Not reported
Watson Investigational Site
Shreveport, Louisiana, United States
Site recruitment: Not reported
Watson Investigational Site
Las Vegas, Nevada, United States
Site recruitment: Not reported
Watson Investigational Site
Mount Laurel, New Jersey, United States
Site recruitment: Not reported
Watson Investigational Site
Voorhees Township, New Jersey, United States
Site recruitment: Not reported
Watson Investigational Site
Albany, New York, United States
Site recruitment: Not reported
Watson Investigational Site
Syracuse, New York, United States
Site recruitment: Not reported
Watson Investigational Site
Lancaster, Pennsylvania, United States
Site recruitment: Not reported
Watson Investigational Site
Myrtle Beach, South Carolina, United States
Site recruitment: Not reported
Watson Investigational Site
Dallas, Texas, United States
Site recruitment: Not reported
Watson Investigational Site
Norfolk, Virginia, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 1CompletedINTERVENTIONAL

SU5416 Plus Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer

ClinicalTrials.gov · NCT00026377 · Registry updated: 2013-09-05

Condition / research focus: Prostate Cancer
Sponsor: University of Chicago
Countries with listed sites: United States
Registry dates and results: Start: 2001-11. Completion: 2003-04 (may be estimated). No results posted in this registry response.

Products and interventions (6)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

bicalutamide (drug)
flutamide (drug)
goserelin acetate (drug)
leuprolide acetate (drug)
SU5416 (drug)
radiation therapy (radiation)

Where the study takes place — 3 listed sites

Radiation Oncology
Chicago, Illinois, United States
Site recruitment: Not reported
University of Chicago Cancer Research Center
Chicago, Illinois, United States
Site recruitment: Not reported
LaGrange Memorial Hospital
LaGrange, Illinois, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 3CompletedINTERVENTIONAL

Tamoxifen, Ovarian Ablation, and/or Chemotherapy in Treating Women With Stage I, Stage II, or Stage IIIA Breast Cancer

ClinicalTrials.gov · NCT00002582 · Registry updated: 2013-08-02

Condition / research focus: Breast Cancer
Sponsor: Institute of Cancer Research, United Kingdom
Countries with listed sites: United Kingdom
Registry dates and results: Start: 1993-06. Completion: 2007-04 (may be estimated). No results posted in this registry response.

Products and interventions (10)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

CMF regimen (drug)
cyclophosphamide (drug)
doxorubicin hydrochloride (drug)
fluorouracil (drug)
goserelin acetate (drug)
leuprolide acetate (drug)
methotrexate (drug)
tamoxifen citrate (drug)
oophorectomy (procedure)
radiation therapy (radiation)

Where the study takes place — 2 listed sites

Cancer Research Campaign Trials Unit-Birmingham (CRCTU)
Birmingham, England, United Kingdom
Site recruitment: Not reported
Beatson Oncology Centre
Glasgow, Scotland, United Kingdom
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Not applicableCompletedINTERVENTIONAL

GnRH-a and Pregnancy Rate in In Vitro Fertilization (IVF) Cycles.

ClinicalTrials.gov · NCT01269125 · Registry updated: 2013-07-30

Condition / research focus: Endometriosis; Infertility
Sponsor: University of Ioannina
Countries with listed sites: Greece
Registry dates and results: Start: 2004-05. Completion: 2010-09 (may be estimated). Results are posted in this registry.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Leuprolide (drug) — also listed as: Daronda depot 3.75, Abbott, Hellas
IVF (procedure)

Where the study takes place — 1 listed sites

Dept. of Obstetrics & Gynecology, University Hospital
Ioannina, Epirus, Greece
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase not reported / not applicableCompletedOBSERVATIONAL

Observational Program to Assess Routine Use of Add-back Therapy in Patients With Endometriosis in Russian Federation, Planned for 6-month Course of Lucrin Depot® (Leuprorelin)

ClinicalTrials.gov · NCT01294371 · Registry updated: 2013-07-22

Condition / research focus: Genital Endometriosis
Sponsor: AbbVie (prior sponsor, Abbott)
Countries with listed sites: Russia
Registry dates and results: Start: 2011-02. Completion: 2012-05 (may be estimated). Results are posted in this registry.

Products and interventions (0)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Where the study takes place — 28 listed sites

Site Reference ID/Investigator# 51643
Chelyabinsk, Russia
Site recruitment: Not reported
Site Reference ID/Investigator# 50577
Irkutsk, Russia
Site recruitment: Not reported
Site Reference ID/Investigator# 50561
Izhevsk, Russia
Site recruitment: Not reported
Site Reference ID/Investigator# 50560
Kazan', Russia
Site recruitment: Not reported
Site Reference ID/Investigator# 50570
Moscow, Russia
Site recruitment: Not reported
Site Reference ID/Investigator# 50567
Moscow, Russia
Site recruitment: Not reported
Site Reference ID/Investigator# 50565
Moscow, Russia
Site recruitment: Not reported
Site Reference ID/Investigator# 50564
Moscow, Russia
Site recruitment: Not reported
Site Reference ID/Investigator# 62184
Nizhny Novgorod, Russia
Site recruitment: Not reported
Site Reference ID/Investigator# 50558
Nizhny Novgorod, Russia
Site recruitment: Not reported
Site Reference ID/Investigator# 50557
Orenburg, Russia
Site recruitment: Not reported
Site Reference ID/Investigator# 50545
Perm, Russia
Site recruitment: Not reported
Site Reference ID/Investigator# 53156
Perm, Russia
Site recruitment: Not reported
Site Reference ID/Investigator# 50547
Saint Petersburg, Russia
Site recruitment: Not reported
Site Reference ID/Investigator# 50548
Saint Petersburg, Russia
Site recruitment: Not reported
Site Reference ID/Investigator# 50549
Saint Petersburg, Russia
Site recruitment: Not reported
Site Reference ID/Investigator# 50551
Saint Petersburg, Russia
Site recruitment: Not reported
Site Reference ID/Investigator# 50552
Saint Petersburg, Russia
Site recruitment: Not reported
Site Reference ID/Investigator# 50556
Samara, Russia
Site recruitment: Not reported
Site Reference ID/Investigator# 50555
Saratov, Russia
Site recruitment: Not reported
Site Reference ID/Investigator# 50554
Stavropol, Russia
Site recruitment: Not reported
Site Reference ID/Investigator# 50580
Stavropol, Russia
Site recruitment: Not reported
Site Reference ID/Investigator# 50579
Tyumen, Russia
Site recruitment: Not reported
Site Reference ID/Investigator# 50575
Vladivostok, Russia
Site recruitment: Not reported
Site Reference ID/Investigator# 50562
Volzhskiy, Volgograd Region, Russia
Site recruitment: Not reported
Site Reference ID/Investigator# 48866
Voronezh, Russia
Site recruitment: Not reported
Site Reference ID/Investigator# 54502
Voronezh, Russia
Site recruitment: Not reported
Site Reference ID/Investigator# 50563
Yekaterinburg, Russia
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Worldwide Study Finder

Find a study

Registry search results

Neo-adjuvant Abiraterone + Luteinizing Hormone-Releasing Hormone (LHRH) Versus LHRH in Prostate Cancer

Explore the world’s study registries

Worldwide

Africa

Americas

Influence of Male Hormones on Regional Fat Metabolism

A Long-term Extension Study of TAK-385 in the Treatment of Endometriosis

The Effect of GnRH Agonist Administered in the Luteal Phase on ART Cycle Outcomes

The JET Study: a Phase I Trial of Cabazitaxel, Radiotherapy and Long-term Androgen Deprivation

The ELDORADO (Eligard®, Docetaxel and Radiotherapy) Study

Androgen Suppression Combined With Elective Nodal and Dose Escalated Radiation Therapy

Efficacy and Safety of TAK-385 in the Treatment of Endometriosis

Medical Treatment of Endometriosis-Associated Pelvic Pain

The Comparison of Effect of Four Different Treatment Protocols on IVF Outcomes in Poor Responders Undergoing in Vitro Fertilization.

Observational, Non-interventional, Non Comparative Real Life Data Collection of Depo-Eligard® 7.5 mg, 22.5 mg and 45 mg in Male Prostate Cancer Patients

Safety Extension Study Of Leuprolide Acetate (Lupron Depot) In The Treatment Of Central Precocious Puberty

Hormone Therapy Plus Radiation Therapy in Treating Patients With Prostate Cancer

Tamoxifen, Ovarian Ablation, and/or Combination Chemotherapy in Treating Premenopausal Women With Stage I, Stage II, or Stage IIIA Invasive Breast Cancer

A Study of Androgen Deprivation With Leuprolide, +/- Docetaxel for Clinically Asymptomatic Prostate Cancer Participants With a Rising Prostate Specific Antigen (PSA)

Randomized Crossover Trial to Assess the Tolerability of Gonadotropin Releasing Hormone (GnRH) Analogue Administration

SU5416 Plus Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer

Tamoxifen, Ovarian Ablation, and/or Chemotherapy in Treating Women With Stage I, Stage II, or Stage IIIA Breast Cancer

GnRH-a and Pregnancy Rate in In Vitro Fertilization (IVF) Cycles.

Observational Program to Assess Routine Use of Add-back Therapy in Patients With Endometriosis in Russian Federation, Planned for 6-month Course of Lucrin Depot® (Leuprorelin)

Asia

Middle East

Europe

Oceania